Effectiveness of AMSA alone or in combination with radiation on murine fibrosarcoma pulmonary nodules.
The cytotoxic effects in vivo of 4'-(9-acridinylamino) methanesulfon-m-anisidide (AMSA), radiation or both modalities in combination on murine fibrosarcoma (FSa) cells grown as pulmonary tumors were determined. Fourteen days following the i.v. injection of viable FSa cells, recipient mice developed between 100 and 150 visible pulmonary nodules. At that time, tumor-bearing animals were exposed to either single or combined modality treatments, as well as single and fractionated dose regimens. Animals were sacrificed 1 hour after the last treatment. Tumor nodules were excised, made into a single cell suspension and separated on the basis of cell size by centrifugal elutriation. Flow microfluorometry (FMF) was used to determine the cell-cycle parameters and the relative synchrony of the separated populations, as well as the percentage contamination by normal diploid cells in each of the tumor cell populations. Known numbers of viable cells from each elutriator fraction were injected into recipient mice to determine their colony-forming efficiency (CFE). Surviving fractions were determined by comparing the CFEs of treated FSa cells from each of the separated elutriator fractions with those of appropriate untreated controls. Following a single i.v. dose of AMSA (30 mg/kg), populations of cells enriched in S phase were the most sensitive. When a single dose of AMSA was combined with a single dose of radiation (100 rad), there was a marked schedule dependence with the more effective sequence, especially if a 12 hour interval was chosen between doses, being AMSA followed by irradiation. No schedule dependence was observed if both modalities were combined and administered under a fractionated protocol of four fractions of AMSA (5 mg/kg per fraction) and four fractions of radiation (300 rad per fraction). Under these conditions the greatest reduction in CFE was in cell subpopulations most enriched in S and G2 + M phase cells.
D000609:Aminoacridines / Q000627:therapeutic use*; D000677:Amsacrine; D000818:Animals; D002453:Cell Cycle; D002470:Cell Survival / Q000187:drug effects; D003114:Colony-Forming Units Assay; D003131:Combined Modality Therapy; D004273:DNA, Neoplasm / Q000032:analysis; D004334:Drug Administration Schedule; D005260:Female; D005354:Fibrosarcoma / Q000532:radiotherapy / Q000628:therapy*; D005434:Flow Cytometry; D008175:Lung Neoplasms / Q000532:radiotherapy / Q000628:therapy*; D051379:Mice; D008809:Mice, Inbred C3H; D013997:Time Factors
D000609:Aminoacridines; D004273:DNA, Neoplasm; D000677:Amsacrine